Belimumab in Remission of VASculitis

Completed · Phase 3 · Has a placebo group

Conditions studied: Vasculitis

In brief

The purpose of this study is to evaluate the efficacy and safety of belimumab, in combination with azathioprine, for the maintenance of remission following a standard induction regimen in patients with Wegener's granulomatosis or microscopic polyangiitis. The random assignment in this study is "1 to 1" which means that participants have an equal chance of receiving belimumab or placebo.

Key facts

Study ID

NCT01663623

Run by

Human Genome Sciences Inc., a GSK Company

People needed

106

Starts

2013-03-20

Expected to finish

2017-02-06

Last updated by the study team

2018-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• GSK Investigational Site — Mobile, Alabama, United States
• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Covina, California, United States
• GSK Investigational Site — Palo Alto, California, United States
• GSK Investigational Site — San Leandro, California, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Kansas City, Kansas, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — West Springfield, Massachusetts, United States
• GSK Investigational Site — Detroit, Michigan, United States
• GSK Investigational Site — Rochester, Minnesota, United States
• GSK Investigational Site — Camden, New Jersey, United States
• GSK Investigational Site — Great Neck, New York, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Columbus, Ohio, United States
• GSK Investigational Site — Portland, Oregon, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Pittsburgh, Pennsylvania, United States
• GSK Investigational Site — Wyomissing, Pennsylvania, United States
• GSK Investigational Site — Milwaukee, Wisconsin, United States
• GSK Investigational Site — Garran, Australian Capital Territory, Australia
• GSK Investigational Site — New Lambton, New South Wales, Australia
• GSK Investigational Site — Malvern, Victoria, Australia
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.